Summary A class of new 5-fluorouracil (FU) analogues, the 5-fluoro-5,6-dihydro-6-alkoxy-uracils was synthesised with a modification at the 6-position of the pyrimidine ring. At this position the analogues have a hydroxy or alkoxy group of different chain lengths either in the cis-or trans-configuration. The antiproliferative effect of these compounds was tested on five cell lines of different origin. Generally, the analogues with a cis-configuration had a higher activity than those with a trans-configuration. The growth inhibitory effect of the compounds decreased with increasing alkoxy chain length, but the compound with a hydroxy group had the lowest growth inhibitory effect. One analogue, cis-5-F-5,6-dihydro-6-methoxy-uracil had a higher antiproliferative effect than FU in one of the cell lines. Effects on thymidylate synthase (TS), the possible target of these analogues, were evaluated by thymidine rescue of growth inhibition and incorporation of tritiated deoxyuridine (3H-UdR) into DNA. In solid tumour cell lines addition of TdR reversed the antiproliferative effect. Inhibition of TS in intact cells was determined by measuring 3H-UdR incorporation in two cell lines. The effect of cis-5-F-5,6-dihydro-6-methoxy-uracil on incorporation of 3H-UdR was 2-to 5-fold stronger than that of FU in both cell lines. All other compounds produced a higher 3H-UdR incorporation than FU both at equimolar and equi-toxic concentration. Concluding from these results we regard cis-5-F-5,6-dihydro-6-methoxy-uracil as the most promising FU analogue of this series, because of its higher antiproliferative activity than FU and marked inhibition of TS in intact cells.
Since its introduction as an antineoplastic agent 5-fluorouracil (FU) has been used for the treatment of a wide spectrum of solid tumours. However, objective response rates are moderate, being lower than 20% in controlled randomised trials of advanced colorectal cancer treatment and cures are rarely achieved (Weckbecker, 1991; Peters & Van Groeningen, 1991a) . Several approaches have been used to increase this therapeutic index, such as combination with other anticancer drugs, biochemical modulation of the FU metabolism (Peters & Van Groeningen, 1991a) and synthesis of more potent analogues (Heidelberger et al., 1983) . All these studies are based on thorough research on the mechanism of action of FU, that has been performed during the last three decades (Pinedo & Peters, 1988; Diasio & Harris, 1989; Weckbecker, 1991) .
The mechanism of action of FU is rather complicated and involves conversion to nucleotides. One of the most important nucleotides for antitumour activity is 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP) , which blocks DNA synthesis through the inhibition of thymidylate synthase (TS, E.C.2.1.1.45), by the formation of a stable ternary complex with FdUMP and the cofactor 5, 10-methylenetetrahydrofolate. Other nucleotides, that play a role in FU activity are 5-fluorouridine-5'-triphosphate (FUTP) and 5-fluoro-2'-deoxyuridine-5'-triphosphate (FdUTP). Incorporation of FUTP into RNA has been associated with both antitumour effect and gastrointestinal/myeloid toxicity. Whether incorporation of FdUTP into DNA, leading to DNA strand breaks and DNA fragmentation, really contributes to the antitumour effect could not be established until now (Pinedo & Peters, 1988) . Supported by findings that a low inhibition of TS in tumours of patients treated with FU may be related to poor prognosis (Spears et al., 1988) , and that an enhanced antitumour effect seems to be related to a better inhibition of TS (Swain et al., 1989; Peters et al., 1991b Peters et al., , 1992 , TS became an important target. Further research on TS and its inhibitors, included biochemical modulation of FU therapy with the folate cofactor precursor, folinic acid leading to an enhanced TS inhibition and an increase in the response (Swain et al., 1989) . This has promoted the development of potent analogues of the folate cofactor (Harrap et al., 1989) . Research concentrated to a lesser extent on analogues of FdUMP (Rode et al., 1990) or nucleotides of FU analogues (Heidelberger et al., 1983) .
The early studies of FU derivatives were focused on the direction of FU precursors or prodrugs. These compounds are supposed to generate their activity by a more selective conversion to FU and/or its metabolites in tumour tissues.
Examples of this group are floxuridine (5-fluoro-2'-deoxyuridine) (Heidelberger et al., 1958) , ftorafur (NI-tetrahydrofuran-2-yl-5-fluorouracil) (Blokhina et al., 1972) and doxifluridine (5'-deoxy-5-fluorouridine) (Cook et al., 1979) . These compounds did not show a clear therapeutic advantage over FU in systemic application (Weckbecker, 1991;  Grem, 1990) , although for some compounds the most optimal administration schedule has not (yet) been established (De Bruijn et al., 1989) .
Recently we described the synthesis and in vitro antitumour activity of a series of 5-fluorinated nucleosides (Visser et al., 1988; Braakhuis et al., 1991) . In order to obtain more potent drugs in the class of fluorinated pyrimidines, we therefore synthesised a new series of compounds based on the structure of FU. The new analogues have a modification at the 6-position of the pyrimidine ring. The 5-F-5,6-dihydro-6-OR-uracil compounds have a R substitution of an hydroxy or alkoxy group of various chain length either in the cis-or trans-configuration (Figure 1 ). The rationale to develop this new series was to have an analogue that, due to the absence of a 5,6-double bound, is not directly a target for dihydropyrimidine dehydrogenase (DPD). DPD is an important catabolic enzyme, which inactivates a large part (up to 90%) of a FU dose in vivo, before it can reach the tumour (Diasio & Harris, 1989) . Chemically the group at the 6-position of the analogue appeared to be susceptible to substituted, so theoretically in cells this could be substituted by the SH-group of TS. In addition, apart from the fact that the group at the 6-position creates a potentially interesting difference in lipophilicity, chemically the trans compound was found to be more stable than its corresponding cis compound. Finally the N'H-group is still free and no problem with conversion to nucleosides and subsequently to nucleotides should theoretically occur. This implies that these compounds are no FU prodrugs.
This study describes the antiproliferative effect in vitro of these 5-fluoro-5,6-dihydro-6-alkoxy-uracil adducts. Each compound has also been tested for its capacity to inhibit TS, the possible target for antitumour effect.
Materials and methods

Synthesis
The basic structure of 5-F-5,6-dihydro-6-alkoxy-uracil and the synthetic route are shown in Figure 1 . The detailed synthesis of the 5-F-5,6-dihydro-6-alkoxy-uracil compounds, their conformation and their chemical properties will be described elsewhere, together with analysis and further characteristics. In short, the 5-F-5,6-dihydro-6-OAc-uracil adduct is formed from the reaction of gaseous AcOF with uracil in acetic acid (Visser et al., 1986) . Under acidic conditions (H2SO4) reaction of the 5-F,6-OAc adduct with ROH resulted within 15min at 80°C in predominantly the corresponding cis-5-F-5,6-dihydro-6-alkoxy-uracil compounds; prolonged heating increased the amount of the trans compound resulting in a cis/trans ratio of about two. After addition of an aqueous K2CO3 solution until pH = 3, the solvent was rotoevaporated and the cis/trans compounds were separated by column chromatography (Visser et al., 1986) (Carey, 1985) . A third cell line C26-10 (doubling time 18 h), was a gift from Dr Klohs (Klohs & Steinkampf, 1988) and was originally derived from a undifferentiated murine colon carcinoma (Corbett et al., 1975 (DMEM, Flow) . DMEM and RPMI medium were supplemented with 10% heat inactivated foetal calf serum (FCS) (Gibco, New York, USA), and 1 mM L-glutamine. During experiments 100 U ml-' penicillin and 100 gig ml-' streptomycin were added to the culture medium.
Growth inhibition tests Cells from routine, subconfluent cultures were transferred to 96-well flat-bottom plates (Greiner Labortechnik, Solingen, Germany) (C26-10, UM-SCC-1 lB and UM-SCC-14C) or round-bottom plates (Greiner) (Wl-L2 and WI-L2:Cl). For the UM-SCC-I1B and UM-SCC-14C cell density was 1500 cells/well in 150gil medium. After a lag-phase of 72 h, 50gil of drug containing medium was added. C26-10 cells were plated at a density of 1000 cells/well in 100 gil and after 24 h 1001il drug containing medium was added. W1-L2 and Wl-L2:C1 were seeded at a density of 10,000 cells/well in 50gil and 1 h later 50gil drug containing medium was added. For the thymidine (TdR) rescue experiments 10 giM (final concentration) was added simultaneously with FU or one of the analogues. Drug exposure time was 72 h for all cell lines. The drugs were tested in triplicate at concentrations ranging from 10-' to 10-8 M. Growth inhibitory effects were evaluated with the standard sulforhodamine B (SRB) assay (Skehan et al., 1990; Keepers et al., 1991) for C26-10, UM-SCC-1 B and UM-SCC-14C and with the MTT assay (Pieters et al., 1988) The incorporation of [6-3H]-deoxyuridine (3H-UdR) (Amersham International, Buckinghamshire, UK; specific activity 17 Ci mmol-1) into DNA was measured in two of the solid tumour cell lines with the lowest and highest TS activity, UM-SCC-14C and C26-10, respectively. Two concentrations of each 5-F-5,6-dihydro-6-alkoxy-uracil compound were tested and compared to the effect of FU. All compounds were tested at the concentration causing 50% growth inhibition (equi-toxic) and at the equimolar concentration of 1 gM. The assay was performed as described previously (Peters et al., 1987; Braakhuis et al., 1991) . Cells (105/well in 100 p1) were seeded in 96-well filtration plates coated with a hydrophilic PVDF filter with 0.22 ym pore size (Millipore Corporation, Bedford, MA, USA). After 24 h 100 p1l drug containing medium was added and the cells were incubated with the drug for 1 h. Then 10 p1l 10 IlM 3H-UdR (0.5 ,uCi; specific activity 4.5 Ci mmol 1) was added. After another 2 h incubation the plate was put on a Millipore vacuum holder and the medium was filtered through the membrane of the wells using a vacuum pump. Next, the cells were precipitated by addition of 200 p1 ice-cold 8% trichloroacetic acid (TCA), followed by three washes with 8% ice-cold TCA, four washes with water and subsequently with 70% ethanol (4 x). After drying by cold air the filters were collected with a multiple punch assembly (Millipore), and 500 pl 2 M NaOH was added to solubilise the precipitated nucleic acids. Finally radioactivity was counted after addition of 5 ml Optiphase III (Hisafe) liquid scintillation fluid (LKB, Woerden, The Netherlands). Values were corrected for non-specific binding of 3H-UdR.
Results
Growth inhibition
The antiproliferative effect of the 5-F-5,6-dihydro-6-alkoxyuracil compounds compared to FU in the three solid tumour cell lines has been summarised in Figure 2 . All compounds were tested on UM-SCC-14C and UM-SCC-IIB, because of previous testing of fluoropyrimidine analogues in these cells (Braakhuis et al., 1991) . Besides this, because of different sensitivity for FU, these cell lines form a good model to get an insight in the spectrum of activity of the new drugs.
FU appeared to be the most active drug in these two cell lines. In general the analogues with a cis-configuration (the UM-SCC-1 1 B UM-SCC-1 4C
odd numbers 1-7) had a higher growth inhibitory effect than the analogues with a trans-configuration (the even numbers). The antiproliferative effect of the compounds decreased with increasing chain length of the alkoxy substitution, which was illustrated by the step-like pattern of compounds number 2, 4, 6 and 8 (Figure 2 ). Cis-5-F-5,6-dihydro-6-hydroxy-uracil(9) showed a very poor growth inhibitory effect in these two cells lines. For C26-10 (Figure 2) , the third solid tumour cell line in the panel only cis-5-F-5,6-dihydro-6-methoxy-uracil(l) and cis-5-F-5,6-dihydro-6-ethoxy-uracil(3), the most promising active compounds from the previous growth inhibition tests, were tested. Cis-5-F-5,6-dihydro-6-hydroxy-uracil(9) was included as a negative control, in view of its very low activity in the other two cell lines. Interestingly, the analogue cis-5-F-5,6-dihydro-6-methoxy-uracil(l) had a striking effect on C26-10, with a better growth inhibition than FU at equimolar concentration. Additionally TdR rescue experiments were performed to evaluate whether growth inhibitory effects mediated by TS, could be circumvented by the addition of 10 gM TdR. For these experiments we included the lymphoblastoid cell lines in the panel. WI-L2:Cl, which has a very high TS expression, might be a good cell line to study TS related growth inhibition. Results on the TdR rescue are summarised in Table I . The dose modifying factor (IC50 of drug+TdR/IC50 of drug alone) varied for each compound and the cell line. Generally TdR rescued growth inhibition mediated by all compounds in UM-SCC-1 lB, UM-SCC-14C and C26-10 (except compound no. 9), although not always the level of significance was achieved. The lymphoblastoid cell lines did not differ very much with respect to their sensitivity for FU and the analogues (Figure 2 ) and TdR rescue was very limited in these cell lines (Table I) .
Thymidylate synthase activity The activity of TS was measured firstly as the number of binding sites to TS for FdUMP, the active nucleotide of FU and secondly as the catalytic activity to convert its natural substrate dUMP to dTMP. The results of both assays, measured in cells that were not exposed to FU, were very different for each cell line (Table II) . The FdUMP binding capacity of the fast growing C26-10 cell lines was about 4-fold higher than that of UM-SCC-11B and about 20-fold higher than that of UM-SCC-14C. For the catalytic activity -dihydro-6-methoxy-uracil; 2 = trans-5-F-5,dihydro-6-methoxy-uracil; 3 = cis-5-F-5,6-dihydro-6-ethoxy-uracil; 4 = trans-5-F-5,6-dihydro-6-ethoxy-uracil; 5 = cis-5-F-5,6-dihydro-6-n-propoxy-uracil; 6 = trans-5-F-5,6-dihydro-6-n-propoxy-uracil; 7 = cis-5-F-5,6-dihydro-6-i-propoxy-uracil; 8 = trans-5-F-5,6-dihydro-6-i-propoxy-uracil; 9 = cis-5-F-5,6-dihydro-6-hydroxy-uracil. Statistics (Student's t-test for unpaired data); in UM-SCC-1 B the following compounds had a significantly smaller antiproliferative effect than FU, no. 5, P <0.02; no. 6, P <0.05; no. 8, P <0.01 and no. 9, P <0.001. In UM-SCC-14C FU was significantly more active than the trans-5-F-5,6-dihydro-6-alkoxy-uracii compounds (no. 2, 4, 6, P<0.05; no. 8, P<0.001; no. 9, P<0.01). In C26-10 compound no. 1 was significantly more active than FU (P<0.001), while the other two, compounds no. 3 and 9 were less active than FU (P<0.001). In WI-L2 and Wl-L2:Cl compound no. 9 was significantly less active than FU (P <0.001). Figure 2 for compound number and name). pmol h-' mg-' protein, respectively).
3H-UdR incorporation
In order to determine whether these compounds exerted their antiproliferative effect through the inhibition of TS, we measured the incorporation of 3H-UdR into DNA. [6-3H]-UdR is converted into [6-3H]-dUMP, followed by a TS catalysed formation of [6-3H]-dTMP, one of the precursors for DNA synthesis. Inhibition of TS reduced the amount of 3H incorporated into DNA of both UM-SCC-14C cells ( Figure  3 ) and C26-10 cells (Figure 4 ) with a relatively low and high TS activity, respectively.
The analogues were tested at a concentration of I .LM. This is equimolar to the IC50 of FU after 72 h drug exposure in both cell lines. Although, the drug exposure time in this assay was only 3 h, exposure to I JAM FU resulted already in about 50% inhibition of 3H-UdR incorporation, because inhibition of TS is a fast event and precedes growth inhibition. Thus this method can be used as a fast screening test for inhibitory effects on thymidylate synthesis. At the equimolar concentration only FU, cis-5-F-5,6-dihydro-6-methoxyuracil(1) and cis-5-F-5,6-dihydro-6-n-propoxy-uracil(5) reduced 3H-UdR incorporation in UM-SCC-14C (Figure 3a) . At equi-toxic concentration (the IC50 concentration of each compound after 72 h drug exposure) cis-5-F-5,6-dihydro-6-npropoxy-uracil(5) and cis-5-F-5,6-dihydro-6-hydroxy-uracil(9) produced a reduction of 3H-UdR incorporation into the DNA of UM-SCC-14C cells comparable to that of FU (Figure 3b ). Three hours incubation of UM-SCC-14C cells with cis-5-F-5,6-dihydro-6-methoxy-uracil(l) resulted in an even better reduction of 3H-UdR incorporation than incubation with FU, during the same period.
In C26-10 cells exposure to cis-5-F-5,6-dihydro-6-methoxyuracil(l) at equimolar concentration resulted in an incorporation significantly lower than control (P<0.05) (Figure 4a) . The other two drugs and also FU did not reduce the 3H-UdR incorporation at this concentration and short exposure time. At equi-toxic concentration only cis-5-F-5,6-dihydro-6- methoxy-uracil(1) produced a 50% reduction of 3H-UdR incorporation, while the other compounds hardly affected the incorporation. Generally, at equi-toxic concentrations the analogues, but also FU had a stronger effect on the 3H-UdR incorporation into DNA of UM-SCC-14C cells than on that of C26-10 cells.
Discussion
The antiproliferative effect of one of the FU analogues tested in this study, 'cis-5-F-5,6-dihydro-6-methoxy-uracil' showed a higher activity than FU in C26-10 ( Figure 2) . Most of the other compounds also exhibited growth inhibitory capacities, but higher concentrations were necessary to obtain effects comparable to FU. The observation that the compounds with a cis-configuration were generally more potent than those with a trans-configuration is most probably related to chemical stability against nucleophilic substitution of the C6-group, which is higher for compounds with a trans-configuration (Visser et al., 1992) . In the cis-series chemically no difference in substitution rate at C6 was observed for analogues with a methoxy, ethoxy, n-propoxy or i-propoxy group. So the decreasing antiproliferative effect in the cisseries with increasing chain length might indicate the occurrence of steric hindrance of the longer alkoxy chain during the approach of the C6-centre by the SH-group of the TS enzyme.
The effect of the new analogues on their possible target, TS, was investigated in two ways, the rescue of growth inhibition by TdR, which would show that dTMP depletion caused by inhibition of TS was a main factor for the antitumour effect, and 3H-UdR incorporation into DNA, which could reveal a change in TS activity caused by the drugs. The TdR rescue was clear in the solid tumour cell lines in contrast to the lymphoblastoid cell lines. Besides the absence of TdR rescue, the sensitivities of WI-L2 and WI-L2:Cl for FU and the analogues were comparable despite the large difference in TS levels. These results are in accordance with findings of Jackman et al. (1986) and O'Connor et al. (1992), which show that in cell lines with very high TS, growth inhibition, caused by FU, could not be reversed by TdR, while reversal of growth inhibition, caused by FUdR, was less in the overproducing lines than in the parent lines. The latter phenomenon was explained to be related to an indirect effect on the folate-dependent purine de novo synthesis, which cannot be rescued by TdR alone, but requires the addition of folinic acid and/or hypoxanthine. So unfortunately, the TS overexpressing cell line was not an ideal model to study TdR rescue of growth inhibition mediated by FU-based TS inhibitors.
The incorporation of 3H-UdR was studied in two cell lines (UM-SCC-14C and C26-10) with a 20-fold intrinsic difference in TS activity and a 4-fold difference in doubling time.
However, their IC50 for FU after 72 h exposure were comparable (about I ptM for both cell lines). On the other hand, the short term effect of 1 4M FU on TS, measured after 3 h drug exposure by 3H-UdR incorporation into DNA was larger in UM-SCC-14C cells than in C26-10 cells. This might be due to the high TS levels and the short doubling time of the latter line.
Most of the newly synthesised compounds did not affect the 3H-UdR incorporation into DNA of UM-SCC-14C cells at equimolar concentration (1 fLM), but at IC50 concentrations (equi-toxic) a significant reduction of 3H-UdR incorporation was found for at least six of the nine analogues. The extent of reduced 3H-UdR incorporation at equimolar concentrations is an indication for the inhibition of TS and at least six of these analogues appeared to cause inhibition of TS to a certain extent in UM-SCC-14C cells. Although in C26-10 the effects of FU and the three tested analogues on 3H-UdR incorporation into DNA were less pronounced than in UM-SCC-14C, cis-5-F-5,6-dihydro-6-methoxy-uracil(1) was the most potent inhibitor of 3H-UdR incorporation and thereby of TS, in both cell lines.
Apparently, cis-5-F-5, 6-dihydro-6-methoxy-uracil(l) is cytotoxic without conversion to FU: for at equimolar concentration it had a higher growth inhibitory effect in C26-10 than FU. If the drug firstly had to be metabolised to FU, it could never have been more toxic than FU. The structural similarity of the analogues makes it seem reasonable to assume that the other compounds exert their effect likewise, but of course from the results alone it cannot be concluded whether they are degraded (chemically or enzymatically to FU) or are activated directly to active nucleotides.
So far we may conclude that cis-5-F-5,6-dihydro-6-methoxy-uracil(1) is a potentially interestingly new FU analogue, because it reduced 3H-UdR incorporation to a larger extent than FU, in both tested cell lines. The compound was highly active in the fast growing solid tumour cell line C26-10 (having a high intrinsic TS actvity), while it showed less activity in the slower growing cell lines with lower TS activity. Even in cells with a high acquired TS activity (due to overproduction) a good activity of these pyrimidine based compounds was achieved. These tests demonstrate that cis-5-F-5,6-dihydro-6-methoxy-uracil(1) is a more active drug than FU and a potent TS inhibitor. As a consequence in vivo preclinical tests on antitumour effect and toxic side effects will be performed to evaluate the efficacy of this new FU analogue.
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